{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-003238","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.921240+00:00","generated_at":"2026-06-15T07:43:46.329331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VolitionRx Q1 sales jump 381% to $124k; cash $10M; expects $13M milestones","bullets":["Nu.Q Vet Cancer Test sales rose 381% YoY to $124,000 in Q1 2023.","Cash and equivalents $10.0M at March 31, 2023 vs $10.9M at year-end 2022.","Received ~$8M net from Feb public offering; expects $13M in Heska milestone payments and additional non-dilutive Belgian funding.","Launched Nu.Q Vet Cancer Test through IDEXX and Heska; planning more country launches in 2023.","Advancing Nu.Q NETs test for sepsis with multi-site U.S. studies and FDA Breakthrough Device application."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-003238","json":"https://secwatch.observer/filing/0001477932-23-003238.json","markdown":"https://secwatch.observer/filing/0001477932-23-003238.md","text":"https://secwatch.observer/filing/0001477932-23-003238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793223003238/0001477932-23-003238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793223003238/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:43:46.329331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee6e88d3e60d454e9825a60383e401bdfed33cfc","claim":"VOLITIONRX LTD reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223003238/0001477932-23-003238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}